Brief: Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Vaxcyte Inc expected to post a loss of 84 cents a share - Earnings Preview
Vaxcyte rises as FDA clears marketing application for its pneumococcal vaccine
Brief: Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31
Brief: Vaxcyte And Lonza Expand Collaboration For Global Commercial Manufacturing Of Broad-Spectrum Pneumococcal Conjugate Vaccines(PCVs)
Vaxcyte Inc reports results for the quarter ended in June - Earnings Summary
Brief: Vaxcyte Q2 Operating Expenses USD 87.147 Million
Vaxcyte Inc expected to post a loss of 74 cents a share - Earnings Preview
Brief: Vaxcyte Advances To Second Stage Of Ongoing Phase 2 Study Evaluating VAX-24 For Prevention Of Invasive Pneumococcal Disease In Infants
Brief: Vaxcyte Reports First Quarter 2023 Financial Results And Provides Business Update
Vaxcyte Inc reports results for the quarter ended in March - Earnings Summary
Brief: Vaxcyte Q1 net loss USD 60.462 million
Vaxcyte Inc expected to post a loss of 83 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-CDW Corp, Bed Bath & Beyond, Elevance Health
U.S. STOCKS ON THE MOVE-United Airlines, Abbott Labs, Shift4 Payments
U.S. STOCKS ON THE MOVE-Western Alliance, WeWork, Baker Hughes
Vaxcyte dips after pricing $500 mln stock offering
Brief: Vaxcyte Announces Pricing Of $500 Million Public Offering
Vaxcyte slips on stock offering launch